1-biphenyl-4-yl-3-cyano-thiourea | 760214-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-biphenyl-4-yl-3-cyano-thiourea
• 英文别名: 1-biphenyl-4-yl-3-cyanothiourea；N-cyano-N'-(1-biphenyl-4-yl)thiourea；1-Cyano-3-(4-phenylphenyl)thiourea
• CAS: 760214-53-7
• 化学式: C₁₄H₁₁N₃S
• 分子量: 253.327
• InChiKey: QSGYQZZABRCRDW-UHFFFAOYSA-N

物化性质

• 沸点：
  399.3±35.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-biphenyl-4-yl-3-cyano-thiourea 、 (2R)-2-amino-3-phenyl-N-(3-pyrrolidin-1-ylpropyl)propanamide 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 (R)-2-(N'-biphenyl-4-yl-N''-cyano-guanidino)-3-phenyl-N-(3-pyrrolidin-1-yl-propyl)-propionamide
  参考文献：
  名称：

  新型2型甘氨酸转运蛋白再摄取抑制剂。第1部分：α-氨基酸衍生物。

  摘要：

  制备了多种α-氨基酸衍生物作为甘氨酸转运抑制剂，并评估了它们在人甘氨酸转运蛋白2（hGlyT-2）转染的COS7细胞中阻断[（14）C]-甘氨酸摄取的能力。研究了手性中心的一系列取代基，总的来说，L-苯丙氨酸被确定为优选的氨基酸残基。与衍生自相应的d-氨基酸的类似物相比，由l-氨基酸制备的化合物是更有效的GlyT-2抑制剂。引入非手性氨基酸（例如甘氨酸）或在α位置引入双链取代，会导致GlyT-2抑制特性显着降低。

  DOI：

  10.1016/j.bmc.2004.05.042
• 作为产物：
  描述：

  4-氨基联苯 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 1-biphenyl-4-yl-3-cyano-thiourea
  参考文献：
  名称：

  新型2型甘氨酸转运蛋白再摄取抑制剂。第1部分：α-氨基酸衍生物。

  摘要：

  制备了多种α-氨基酸衍生物作为甘氨酸转运抑制剂，并评估了它们在人甘氨酸转运蛋白2（hGlyT-2）转染的COS7细胞中阻断[（14）C]-甘氨酸摄取的能力。研究了手性中心的一系列取代基，总的来说，L-苯丙氨酸被确定为优选的氨基酸残基。与衍生自相应的d-氨基酸的类似物相比，由l-氨基酸制备的化合物是更有效的GlyT-2抑制剂。引入非手性氨基酸（例如甘氨酸）或在α位置引入双链取代，会导致GlyT-2抑制特性显着降低。

  DOI：

  10.1016/j.bmc.2004.05.042

文献信息

• [EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005044810A1

  公开（公告）日：2005-05-19

  α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I

  公式I的α-, β-, 和 Ϝ-氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统（CNS）疾病，如肌肉痉挛、耳鸣、癫痫和神经痛。
• GlyT2 modulators
  申请人：Barclay K. Tristin

  公开号：US20050119245A1

  公开（公告）日：2005-06-02

  Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.

  某些α、β和γ氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统(CNS)疾病，例如肌肉痉挛、耳鸣、癫痫和神经病痛。
• Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement
  作者：Mirko Buchholz、Antje Hamann、Susanne Aust、Wolfgang Brandt、Livia Böhme、Torsten Hoffmann、Stephan Schilling、Hans-Ulrich Demuth、Ulrich Heiser

  DOI：10.1021/jm900969p

  日期：2009.11.26

  The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of A beta(3,11(pE)-40,42), as these A beta-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of A beta-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of A beta(3,11(pE)-40,42) formation.
• Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives as Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase
  作者：Junsheng Zhu、Le Han、Yanyan Diao、Xiaoli Ren、Minghao Xu、Liuxin Xu、Shiliang Li、Qiang Li、Dong Dong、Jin Huang、Xiaofeng Liu、Zhenjiang Zhao、Rui Wang、Lili Zhu、Yufang Xu、Xuhong Qian、Honglin Li

  DOI：10.1021/jm501127s

  日期：2015.2.12

  Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.
• Novel glycine transporter type-2 reuptake inhibitors. Part 2: β- and γ-amino acid derivatives
  作者：Ronald L Wolin、Alejandro Santillán、Tristin Barclay、Liu Tang、Hariharan Venkatesan、Sandy Wilson、Doo Hyun Lee、Timothy W Lovenberg

  DOI：10.1016/j.bmc.2004.05.043

  日期：2004.8

  Several beta- and gamma-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) were evaluated. A range of lipophilic side chains were tolerated in the beta-amino acid series (i.e., Ph, CH2Ph, CH(CH3)(2), and CH2CH(CH3)(2)). In the gamma-amino acid series, minimal differences in potency were observed between the alpha, beta-unsaturated analogs and the corresponding saturated derivatives. In both series, a 4-biphenyl or 4-phenoxyphenyl substituent appended to the urea or cyanogunaidine moiety was necessary for in vitro activity. (C) 2004 Elsevier Ltd. All rights reserved.